Curasight Valuation

Is CURAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CURAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CURAS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CURAS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CURAS?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for CURAS. This is calculated by dividing CURAS's market cap by their current preferred multiple.
What is CURAS's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	DKK 236.81m

CURAS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-6.7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CURAS's PB Ratio compare to its peers?

The above table shows the PB ratio for CURAS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.6x
XBRANE Xbrane Biopharma	1.3x	130.2%	SEK 340.3m
ALZ Alzinova	3.1x	-67.3%	SEK 324.6m
SYNACT SynAct Pharma	2.1x	n/a	SEK 357.6m
GUARD Guard Therapeutics International	4.1x	-13.5%	SEK 302.5m
CURAS Curasight	18.5x	n/a	DKK 236.8m

Price-To-Book vs Peers: CURAS is expensive based on its Price-To-Book Ratio (18.5x) compared to the peer average (2.6x).

Price to Earnings Ratio vs Industry

How does CURAS's PE Ratio compare vs other companies in the SE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.4%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: CURAS is expensive based on its Price-To-Book Ratio (18.5x) compared to the Swedish Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is CURAS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CURAS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	18.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CURAS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.